ziftomenib
kura oncology
['aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'ziftomenib', 'kura ']
today at the annual congress, we re presenting the latest data on our potential best-in-class menin inhibitor #ziftomenib for npm1-mutant #aml. highlights include 35% complete remission rate and favorable safety profile and tolerability. read more: 
We're working to realize the promise of precision medicines. Our goal is to help patients with cancer lead longer, better lives.